Tweets by @cellcentric

CCS1477 inhibits p300/CBP. Clinical trial for late stage prostate ongoing; haem cancers to follow. pic.twitter.com/jQFekuLq5J

Tim’s collaborative research helped steer CCS1477 for AML. Now heading to the clinic together. pic.twitter.com/lWBDRdMHUS

p300/CBP inhibition impacts IRF4-Myc. CellCentric’s CCS1477 to be tested clinically for haem cancers. pic.twitter.com/aucIY4ZHEc

CellCentric pushing CCS1477 forward for haem applications: cellcentric.com/updates/press-… pic.twitter.com/ngCR7LrANx

CCS1477: potential for both late stage prostate cancer & haems. Clear mech - clinical relevance. pic.twitter.com/16JSQ11ulh

CellCentric presenting at AACR: CCS1477, New Drug on the Horizon. 2 abstracts/posters now also accepted. pic.twitter.com/yoBDVc5dhE